Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy. FE [Internet]. 2025 Mar. 13 [cited 2025 Oct. 28];26(1). Available from: https://journals.seedstm.com/index.php/FE/article/view/1574